Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless

Application Number 10537408

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

				U.S.	PATENTS	Remove
Examiner nitial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	5332720		1994-07-26	Kruger et al.	
	2	5358924		1994-10-25	Kruger, et al.	
	3	5474974		1995-12-12	Kruger et al.	
	4	5661110		1997-08-26	Kruger et al.	
	5	5683965		1997-11-04	Bachmann et al.	
	6	5739389		1998-04-14	Kruger et al.	
	7	5780394		1997-07-14	Kruger et al.	
	8	6410480		2002-06-25	Muhlebach et al.	
f you wis	h to ac	dd additional U.S. Pat	ent citatio	n information p	lease click the Add button.	Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10537408
Filing Date		2005-10-05
First Named Inventor Zeller		, Martin
Art Unit		1621
Examiner Name Puttit		z, Karl J.
Attorney Docket Number		70187

Remove

0.5		U.S.P	S.PATENT APPLICATION PUBLICATIONS				Remove			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Rele	s,Columns,Lines where vant Passages or Releves Appear	
	1									
If you wisi	h to a	dd additional U.S. Publi						d butto		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	199947525	wo			1999-09-23	Novartis-Erfindung- Verwaltungsgesells MBH			
	2	199611574	wo			1996-04-25	Ciba Geigy AG, Gio Jutta	ock,		
	3	199501971	wo			1995-01-19	Bayer AG; Bachma Juergen	m,		
	4	0508126	EP			1992-10-14	Bayer AG			
	5	199621652	wo			1996-07-18	Ciba-Geigy AG			
	6	200078712	wo			2000-12-28	Novartis AG			
	7	199702243	wo			1997-01-23	Bayer Aktiengesells	schaft		

U.S.PATENT APPLICATION PUBLICATIONS

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10537408
Filing Date		2005-10-05
First Named Inventor	Zeller	, Martin
Art Unit		1621
Examiner Name	Puttit	z, Karl J.
Attack on Dealest Month	or	70197

Attorney Docket Number 70187									
	8	60197650	JP		1984-03-16				
If you wisl	h to a	dd additional Foreign P	atent Docum	ent citation	information pl	ease click the Add b	utton Add		
			NON-PA	TENT LITE	ERATURE DO	CUMENTS	Remove		
Examiner Initials*	Cite No	Include name of the ai (book, magazine, journ publisher, city and/or of	nal, serial, sy	mposium,	catalog, etc), o				T6
	William Accods and Duzglas P.Car. "Electronic nature of the Wignermethyl group by 13c and 15f NMR: Nature of any 15f NMR oper first letters in the became an engalative may spreame", JURIAN C. O'FGANCE CHEMISTRY, vol. 44, no. 17 (1979), pp. 3004-17; American Chemical Society, Easter, US; ISSN: 0022-3263, page 3008, examples [2, 3; table].								
	2	Howard E. Zimmerman and Donals R. Dade: "Makesular control of socied cross-conguisted triver restrangements. Exploration yand mechanistic organic periodocensisty's JUSTRALO THE AMERICANA CHEMICAL SCIETY, vol. 101, no. 7, 1979, pages 104-107, JUSTRALO FTHE AMERICANA CHEMICAL SCIETY, vol. 101, no. 7, 1979, pages 104-107, JUSTRALO FTHE AMERICAN CHEMICAL SCIETY, vol. 101, no. 7, 1979, pages 104-107, JUSTRALO FTHE AMERICAN CHEMICAL SCIETY, vol. 101, no. 7, 1979, pages 104-107, pages 10							
	3	Ivo Letto et al. "Spectrophobomenic acisity scale of strong neutral bronsted acids in acetonitrile"; JOURNAL OF ORGANIC CHEMISTRY, vol. 63, no. 22 (1988), pp. 7868-74, XP002146147, American Chemical Society, Easton, US,							
	4	E. B. Troughton et al.: "Coordination, heterolysis, and electron transfer reactions involving delocalised carbocations and carbanions in solution" JOURNAL OF The AMERICAN CHEMICAL SOCIETY, vol. 106, no. 22 (1994) pp. 6728-55, XVIQVE-4164, American Chemical Society, Messinghor, DC, US, issue 10027-863.							
	llamar A Koppel et at: "The gas-phase acidities of very strong neutral bronsted acids"; JOURNAL OF THE AMERICAN OF CHEMICAL SOCIETY vol. 11s, no. 7 (1994) pp. 3047-57; XP002146149, American Chemical Scoety, Washington, DC, US; issn: n0027-963.								
	Winston A Davis and Michael P Cavar A new synthesis of anytmalence/lines*, JOUINAL OF ORGANIC CHEMISTRY, vol. 48 (1983) pp. 2774-5, XP002146150, American Chemical Society, Easton, U.S., Isant: 0022-3263.								
	7 Rudolf Compare and Citic Christman: News synthesis aromatischer koblenwasserstoffe"; CHEMISCHE BERICHTE, vol. 94 (1961) pp. 1795-99; XP002146151, Issur. 0009-2340.								
	8	Martin R Bryce et al. Net tricyanoquinometanimino ORGANIC CHEMISTRY Issn: 0022-3263	es and X-ray o	ystal struct	ures of the trime	thyl and tetramethyl de	erivatives", JOUR		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10537408
Filing Date		2005-10-05
First Named Inventor	Zeller	, Martin
Art Unit		1621
Examiner Name	Puttit	z, Karl J.
Attorney Docket Number		70187

	Yorkasia Taubata et al. "Siegle component organic conductors based on neutral cellula's conclaming the pyrazino-TCNO steleform," JOURNAL, OF GROAND C FEMBETRY, vol. 57, no. 25 (1992) pp. 6749-55); XP002148153, American Chemical Society, Easton, US; Issan. 0022-3263.						
	10	bond	o et al." A new route to phenylenedomalononitrile and the analogu formation" TETRAHEDRON LETTERS, vol. 26, no. 12 (1985) pp. shers, Amsterdam NL; Issn: 0040-4039.				
	11	anion	nari Uno et al, "Paliadium-catalysed 1,4-arylation/alkylation of but s"; JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSAC acal Society, Letchworth, GB; Issa: 0300-922X.				
	12	J. Ch	em. Soc., Chem. Communication 1984, 932-33.				
	13	J. Am	t. Chem. Soc. 121, 1473-78 (1999).				
If you wis	sh to a	dd add	titional non-patent literature document citation information p	lease click the Add	button Add		
	EXAMINER SIGNATURE						
Examine	r Signa	ature		Date Considered			

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10537408		
			2005-10-05		
			, Martin		
			1621		
Examiner Name Puttit		Puttit	Iz, Karl J.		
	Attorney Docket Number		70187		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):	
---	--

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ....

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/JACQUELINE HALEY/	Date (YYYY-MM-DD)	2007-01-11
Name/Print	Jacqueline Haley	Registration Number	41457

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleatert and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.